Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 23;8(10):e020501.
doi: 10.1136/bmjopen-2017-020501.

Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP)

Edurne Mazarico  1   2   3 , Anna Peguero  4 , Marta Camprubí  1 , Carlota Rovira  5 , Maria Dolores Gomez Roig  1   2   3 , Daniel Oros  3   6 , Patricia Ibáñez-Burillo  6 , Jon Schoorlemmer  7 , Narcís Masoller  4 , Maria Dolors Tàssies  8 , Francesc Figueras  4
Affiliations

Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP)

Edurne Mazarico et al. BMJ Open. .

Abstract

Introduction: The incidence of intrauterine growth restriction (IUGR) is estimated at about 3% of pregnancies, and it is associated with 30% of all perinatal mortality and severe morbidity with adverse neurodevelopmental and cardiovascular health consequences in adult life. Early onset IUGR represents 20%-30% of all cases and is highly associated with severe placental insufficiency. The existing evidence suggests that low molecular weight heparin (LMWH) has effects beyond its antithrombotic action, improving placental microvessel structure and function of pregnant women with vascular obstetric complications by normalising proangiogenic and antiapoptotic protein levels, cytokines and inflammatory factors. The objective of our study is to demonstrate the effectiveness of LMWH in prolonging gestation in pregnancies with early-onset IUGR.

Methods and analysis: This is a multicentre, triple-blind, parallel-arm randomised clinical trial. Singleton pregnancies qualifying for early (20-32 weeks at diagnosis) placental IUGR (according to Delphi criteria) will be randomised to subcutaneous treatment with bemiparin 3500 IU/0.2 mL/day or placebo from inclusion at diagnosis to the time of delivery. Analyses will be based on originally assigned groups (intention-to-treat). The primary objective will be analysed by comparing gestational age and prolongation of pregnancy (days) in each group with Student's t-tests for independent samples and by comparing Kaplan-Maier survival curves (from inclusion to delivery, log-rank test). A linear regression model for gestational age at birth will consider the following covariates: gestational age at inclusion (continuous) and pre-eclampsia (binary).

Ethics and dissemination: The study will be conducted in accordance with the principles of Good Clinical Practice. This study was approved by the Clinical Research Ethics Committee (CEIC) of Sant Joan de Déu Hospital, on 13 July 2017. The trial is registered in the public registry www.clinicaltrial.gov. according to Science Law 14/2011, and the results will be published in an open access journal.

Trial registration number: NCT03324139; Pre-results.

Keywords: fetal medicine; prenatal diagnosis; ultrasonography.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Figueras F, Gratacós E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther 2014;36:86–98. 10.1159/000357592 - DOI - PubMed
    1. Baschat AA, Cosmi E, Bilardo CM, et al. . Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol 2007;109:253–61. 10.1097/01.AOG.0000253215.79121.75 - DOI - PubMed
    1. Fisher SJ. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004;2:53 10.1186/1477-7827-2-53 - DOI - PMC - PubMed
    1. Hossain N, Paidas MJ. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin Perinatol 2007;31:208–12. 10.1053/j.semperi.2007.05.002 - DOI - PubMed
    1. Hecher K, Bilardo CM, Stigter RH, et al. . Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001;18:564–70. 10.1046/j.0960-7692.2001.00590.x - DOI - PubMed

Publication types

Associated data